Anti-Rheumatic Drug when Others Have not Worked
Study Description
“A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy”
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in subjects with moderately to severely active psoriatic arthritis (PsA).
Location
Methods
No pharmaceutical medication involved
Recruiting patients only
Biological - placebo for rizankizumab
Placebo for risankizumab administered by subcutaneous (SC) injection
Biological - risankizumab
Risankizumab administered by subcutaneous (SC) injection
Additional Information
Official Study Title
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Clinical Trial ID
NCT03675308
ParticipAid ID
e739re
